## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.0% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($51.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY**
- Source: ts2.tech | 20251231T045701 | Neutral | Relevance: 100%
- Bristol-Myers Squibb shares closed slightly higher on Tuesday amidst thin, year-end trading on Wall Street. Investors are looking ahead to the company's early-January dividend record date and its upcoming quarterly earnings report scheduled for February 5, 2026. The stock's performance reflects a modest gain as the broader market saw slight declines, with analysts noting the convergence of growth rates between technology and other sectors in the coming year.

**2. What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)?**
- Source: Insider Monkey | 20251230T050741 | Bullish | Relevance: 100%
- Bristol-Myers Squibb Company (BMY) received a Buy rating from Guggenheim with a $62.00 price target on December 22, 2025. The company also announced an agreement with the U.S. government to provide Eliquis for free to Medicaid and donate over seven tons of its active pharmaceutical ingredient, ensuring supply chain resilience and addressing key administration priorities. Additionally, the agreement includes direct-to-patient access for certain medications at discounted prices.

**3. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)**
- Source: MarketBeat | 20251231T213741 | Bullish | Relevance: 100%
- Bristol Myers Squibb (NYSE:BMY) experienced unusually high options trading volume on Wednesday, with traders acquiring 180,226 call options, representing a 304% increase over typical volume. This surge in call options indicates elevated bullish interest or hedging activity. The company recently reported solid quarterly results, beating EPS and revenue expectations, provided positive FY2025 guidance, and increased its quarterly dividend to $0.63, yielding approximately 4.7%.

**4. Looking Into Bristol-Myers Squibb Co's Recent Short Interest**
- Source: Benzinga | 20251231T200729 | Neutral | Relevance: 100%
- Bristol-Myers Squibb Co (NYSE: BMY) has experienced a 4.19% increase in its short interest recently, with 35.43 million shares currently sold short, representing 1.74% of its float. This rise indicates a more bearish sentiment among investors, although the company's short interest is still lower than the peer group average of 3.35%. It would take traders an average of 2.16 days to cover their short positions.

**5. VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251231T115428 | Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al significantly increased its stake in Bristol Myers Squibb Company ($BMY) by 43.7% in the third quarter of 2025, now holding 2,234,496 shares valued at $100.78 million. This makes BMY its 29th largest position, comprising approximately 0.7% of its holdings. Other institutional investors also adjusted their positions, and analysts currently rate BMY with a "Hold" consensus and an average price target of $54.62.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.8B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.0 |
| Current P/E | 8.2 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.0% (minimal 5-day change). Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.00% (CS: 60) | Neutral |
| RSI_14 | 63.1 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.098x | Above |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $53.95
- **Stop Loss:** $51.89 (3.8% risk)
- **Target:** $56.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 699
- **Position Value:** $37,711.05
- **Portfolio %:** 37.71%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*